|
1. BIOLOGIE
|
|
|
|
|
2.4 ETIOLOGIE - PORTABLES, ONDES E-M
|
|
|
|
2.6 ETIOLOGIE - ENVIRONNEMENT
|
|
|
|
3.1.1 PRÉVENTION - TABAC - E-CIGS
|
|
|
|
5. TRAITEMENTS
|
|
|
|
5.12 IMMUNOTHÉRAPIES
|
|
|
|
Merck And The Future of Immuno-Oncology: A Chat With Roger Perlmutter [Xconomy]
|
|
|
|
|
|
I would like a much more thorough molecular, cellular description of what happens in a cancer patient who responds to Keytruda. What are the T cells doing that are responsible for this good work? An understanding of those cells could be enormously helpful in getting better combinations with Keytruda. Thus far it’s an embarrassment to say—and I’m embarrassed for the entire scientific community—none of us have been able to achieve this.
|
|
|
|
|
|
|
5.12.1 IMMUNOTHÉRAPIES - PARTENARIATS
|
|
|
|
5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES
|
|
|
|
5.12.5 IMMUNOTHÉRAPIES - PHARMA
|
|
|
|
|
5.2.3 PHARMA - ÉCONOMIE
|
|
|
Five Prime cuts 41 jobs, narrows focus to clinical-stage drugs [Fierce Biotech]
|
|
|
|
|
|
The biotech’s phase 3 candidate bemarituzumab for stomach cancer, a fibroblast growth factor receptor 2 inhibitor partnered with Chinese company Zai Lab, is on the ASCO GI presentation list, along with colony stimulating factor 1 receptor antibody cabiralizumab it is developing with long-term partner Bristol-Myers Squibb.
|
|
|
|
|
|
|
|
5.4 TRAITEMENTS - ECONOMIE
|
|
|
|
5.5.5 ASCO (GASTRO-INTESTINAL)
|
|
|
|
6.1 OBSERVATION
|
|
|
|
6.12 ETHIQUE
|
|
|
Memorial Sloan Kettering Curbs Executives’ Ties to Industry After Conflict-of-Interest Scandals [NY Times]
|
|
|
|
|
|
Debra Berns, the center’s chief risk officer, also said in an email to employees that the hospital’s Board of Overseers and Managers formalized a policy enacted last fall that prohibits board members from investing in start-up companies that Memorial Sloan Kettering helped to found. In addition, it also prevents hospital employees who represent Memorial Sloan Kettering on corporate boards from accepting personal compensation, like equity stakes or stock options, from the companies.
|
|
|
|
|
|
|
6.6 PUBLICATIONS
|
|
|
|
|
6.7.2 APPLIS
|
|
|